Trends in the epidemiology and outcomes for heart failure (HF) are critically important and have not been explicated and compiled in a comprehensive contemporary document. There have been concerning trends in the incidence, prevalence, mortality, and HF hospitalization rates over the past decade. The...
To the Editor: We agree with Drs Gheorghiade and Peterson that hospitalization for acute heart failure (HF) syndromes offers a valuable opportunity to
In patients with heart failure, some organizational and modifiable factors could be prognostic factors. We aimed to assess the association between the in-hospital care pathways during hospitalization for acute heart failure and the risk of readmission. This retrospective study included all elderly patient...
Hospitalization for congestive heart failure: United States, 2000-2010. NCHS data brief No 108. Hyattsville, MD: National Center for Health Statistics, 2012.Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS Data Brief 2012;108:1-8....
Using the US National Hospital Discharge Survey data from National Center for Health Statistics, and Current Population Survey from Census Bureau, we estimated rates of hospitalization for hypertensive CHF patients from 1979-1997.关键词: hypertensive congestive heart failure hospitalization trend ...
Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, ChinaMore Information Abstract ObjectiveTo analyze hospitalization expense and its main influencing factors in heart failure patients with medical insurance and to provide references for controlling the ...
(71,553 patients). The mean age was 64.7 ± 8.4 years, with 65.1% male. Follow-up durations range 9–50 months. Inhibition of SGLT2 resulted in lower composite outcome of heart failure (HF) hospitalization or ...
To the Editor: In their study examining the relationship between statin therapy and the risks for death and hospitalization in chronic heart failure, Dr
(SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hospitalization in high-risk patients with HFrEF. Device therapies may be ...
ContextA predictive model of mortality in heart failure may be useful for clinicians to improve communication with and care of hospitalized